Mother Jones
<!DOCTYPE html PUBLIC “-//W3C//DTD HTML 4.0 Transitional//EN” “http://www.w3.org/TR/REC-html40/loose.dtd”>
Two weeks ago, Turing Pharmaceuticals CEO Martin Shkreli promised to drop the price of Daraprim, a parasite-fighting drug, after raising it from $13.50 a tablet to $750 a tablet. But so far the price tag hasn’t budged.
Shkreli, a former hedge fund manager who acquired Turing in August, first drew criticism after a USA Today article reported the 5,000 percent price hike. He then told ABC News in September that the company would “lower the price of Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit.”
Business Insider writes:
That hasn’t happened yet. A 30-day, 30-pill supply of Daraprim would cost me $27,006 at my local pharmacy.
That boils down to about $900 a pill, which includes the wholesale cost, along with specific pharmacy fees based on the zip code I gave the pharmacy.
So while the price of the drug hasn’t gotten any higher since Shkreli hiked it 5,000%, it hasn’t gotten any lower since he promised to reduce it either. Turing did not respond to Business Insider’s request for clarification about this price.
This article:
The Pharma Jerk We All Hated Last Month Still Hasn’t Dropped the Price of That Drug
